Filing Flows › Lineage Cell Therapeutics (LCTX) › Q2 2026 › vs Q1 2026
Lineage Cell Therapeutics (LCTX) Q2 2026 vs Q1 2026 (quarter over quarter)
Lineage Cell Therapeutics's revenue fell $656K (-38%) from $1.7M in Q1 2026 to $1.1M in Q2 2026. The biggest changes: Collaboration Revenues −$632K (-40%); Royalties License and Other Revenues −$24K (-16%).
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Upfront License Fees | $600K | $860K | −$260K | -30% |
| Event Based Milestones and Other Collaborative Revenue | $343K | $715K | −$372K | -52% |
| Collaboration Revenues | $943K | $1.6M | −$632K | -40% |
| Royalties License and Other Revenues | $126K | $150K | −$24K | -16% |
| Revenue | $1.1M | $1.7M | −$656K | -38% |
| Other income, net | $10.5M | $2.8M | $7.7M | +273% |
| Costs & expenses | $11.5M | $9.3M | $2.2M | +24% |
| Operating costs | $10.0M | $9.3M | $674K | +7% |
| Net earnings | $1.5M | −$4.8M | $6.3M | — |
| Research & development | $4.8M | $4.2M | $540K | +13% |
| General & admin | $5.2M | $5.1M | $134K | +3% |
| Operating cash sources | $10.6M | $4.6M | $5.9M | +127% |
| Depreciation & amortization | $187K | $188K | −$1K | -0.5% |
| Share-based compensation | $1.6M | $1.2M | $429K | +37% |
| Cash used in operations | $7.2M | $8.1M | −$834K | -10% |
| Working capital & other | $10.6M | $4.6M | $5.9M | +127% |
Questions
How much did Lineage Cell Therapeutics's revenue grow quarter over quarter in Q2 2026?
Lineage Cell Therapeutics's revenue fell $656K (-38%) from $1.7M in Q1 2026 to $1.1M in Q2 2026.
What drove Lineage Cell Therapeutics's revenue change in Q2 2026?
Collaboration Revenues −$632K (-40%); Royalties License and Other Revenues −$24K (-16%).